ADC Therapeutics (NYSE:ADCT – Get Free Report) and Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.
Valuation and Earnings
This table compares ADC Therapeutics and Mirum Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ADC Therapeutics | $81.36 million | 2.33 | -$142.62 million | ($0.52) | -2.59 |
| Mirum Pharmaceuticals | $521.31 million | 11.77 | -$23.36 million | ($15.47) | -6.08 |
Mirum Pharmaceuticals has higher revenue and earnings than ADC Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
41.1% of ADC Therapeutics shares are owned by institutional investors. 5.1% of ADC Therapeutics shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
ADC Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
Profitability
This table compares ADC Therapeutics and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ADC Therapeutics | -95.73% | N/A | -28.26% |
| Mirum Pharmaceuticals | -134.75% | -97.25% | -12.59% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for ADC Therapeutics and Mirum Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ADC Therapeutics | 1 | 2 | 3 | 0 | 2.33 |
| Mirum Pharmaceuticals | 1 | 0 | 13 | 1 | 2.93 |
ADC Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 271.75%. Mirum Pharmaceuticals has a consensus target price of $155.56, indicating a potential upside of 65.51%. Given ADC Therapeutics’ higher probable upside, equities research analysts clearly believe ADC Therapeutics is more favorable than Mirum Pharmaceuticals.
Summary
Mirum Pharmaceuticals beats ADC Therapeutics on 8 of the 14 factors compared between the two stocks.
About ADC Therapeutics
ADC Therapeutics is a biotechnology company headquartered in Epalinges, Switzerland. It develops antibody-drug conjugates (ADCs), medicines designed to use antibodies to deliver cell-killing agents to cancer cells. Its research has focused on blood cancers and solid tumors. The company’s lead product, ZYNLONTA (loncastuximab tesirine-lpyl), is an ADC that targets CD19. In the United States, it is approved for adults with relapsed or refractory large B-cell lymphoma after they have received two or more prior systemic treatments.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
